ImmunoPrecise Antibodies Ltd.: Diferență între versiuni
ImmunoPrecise Antibodies Ltd. (modificare)
Versiunea de la data 21 septembrie 2024 17:07
, 21 septembrieThe LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).
Admin (discuție | contribuții) (Pagină nouă: Pagina dedicata companiei ImmunoPrecise Antibodies Ltd. listata cu simbolul CA.IPA ==Descriere companie== ImmunoPrecise Antibodies Ltd. (https://immunoprecise.com/) is a technology platform company that is engaged in the full-service therapeutic antibody discovery. The Company is focused on offering species-agnostic advancements, such as the B cell Select single-cell interrogation technology, DeepDisplay custom phage libraries, as well as the Abthena bispecific program. Its...) |
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
||
| Linia 2: | Linia 2: | ||
==Descriere companie== | ==Descriere companie== | ||
ImmunoPrecise Antibodies Ltd. (https://immunoprecise.com/) is a technology platform company that is engaged in the full-service therapeutic antibody discovery. The Company is focused on offering species-agnostic advancements, such as the B cell Select single-cell interrogation technology, DeepDisplay custom phage libraries, as well as the Abthena bispecific program. Its geographical segments include United States of America, Canada and Europe. The Company’s Antibody Discovery offers design, immunization, characterization and optimization, and preclinical services. The Company offers mammalian protein expression and purification services as stand-alone or in combination after an antibody discovery project to produce the number of antibodies that need for further work. Its mammalian rPEx platform allows the production of all kinds of proteins, including difficult-to-express proteins, Fc-fusion proteins and bispecific antibodies. | ImmunoPrecise Antibodies Ltd. (https://immunoprecise.com/) is a technology platform company that is engaged in the full-service therapeutic antibody discovery. The Company is focused on offering species-agnostic advancements, such as the B cell [[SELECT|Select]] single-cell interrogation technology, DeepDisplay custom phage libraries, as well as the Abthena bispecific program. Its geographical segments include United States of America, Canada and Europe. The Company’s Antibody Discovery offers design, immunization, characterization and optimization, and preclinical services. The Company offers mammalian protein expression and purification services as stand-alone or in combination after an antibody discovery project to produce the number of antibodies that need for further work. Its mammalian rPEx platform allows the production of all kinds of proteins, including difficult-to-[[express]] proteins, Fc-fusion proteins and bispecific antibodies. | ||
==Grafic actiuni companie== | ==Grafic actiuni companie== | ||